Omalizumab for chronic urticaria in Latin America
Abstract Background Chronic urticaria (CU) is defined as the spontaneous appearance of wheals, with or without angioedema, persisting for ≥6 weeks. Chronic Spontaneous Urticaria (CSU) is a type of CU which affects 0.5–1 % of the global population, but it represents a high burden to patients. In rece...
Main Authors: | Paul Wilches, Paola Wilches, Juan Carlos Calderon, Annia Cherrez, Ivan Cherrez Ojeda |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-11-01
|
Series: | World Allergy Organization Journal |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40413-016-0127-y |
Similar Items
-
Omalizumab in the treatment of chronic spontaneous urticaria – literature review and own experience
by: Joanna Dawicka, et al.
Published: (2016-02-01) -
Treatment of chronic urticaria with omalizumab: the experience of Hospital de Braga
by: Ana G. Lopes, et al.
Published: (2022-10-01) -
Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria
by: Nadja Højgaard Pedersen, et al.
Published: (2023-07-01) -
Efficacy of Different Dosing Regimens of IgE Targeted Biologic Omalizumab for Chronic Spontaneous Urticaria in Adult and Pediatric Populations: A Meta-Analysis
by: Humayun Manzoor, et al.
Published: (2022-12-01) -
Omalizumab treatment in a 12 year-old girl with chronic spontaneous urticaria
by: Giuseppe Fabio Parisi, et al.
Published: (2018-12-01)